Neuroendocrine Cancer – Drug Pipeline Landscape, 2023
Neuroendocrine Cancer is also called as neuroendocrine tumor (NET) arise from the specialized cells in the neuroendocrine system. These cells combine the traits of nerve cells and hormone-producing endocrine cells. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lungs, and rest of the body.
Neuroendocrine Cancer exact cause is not known. However, there are certain risk factors for developing NST, such as inherited syndromes such as multiple endocrine neoplasia type 1 (MEN1), which includes NETs, GI tract NET, and pancreatic NET.
Other hereditary conditions associated with NEC include Von Hippel-Lindau syndrome, neurofibromatosis type 1, and tuberous sclerosis complex. Other medical conditions, such as stomach diseases and a decrease in acid production, as well as environmental factors and diet, are linked to the development of NET.
Neuroendocrine Cancer cause symptoms based on their location and whether or not they are functional. A common symptom includes flushing (redness, warmth) in the face or neck without sweating, diarrhea, unclosing at nighttime, shortness of breath, rapid heartbeat or palpitations, high blood pressure, fatigue, weakness, abdominal pain, cramping, weight gain or loss, and swelling in the feet and ankles.
Neuroendocrine Cancer diagnosis initially involves the history of symptoms and performing a basic examination, including swollen lymph nodes. Later, it moves to CT scans and MRI imaging tests. Finally, a biopsy is performed to determine the grade of the tumor and the severity.
Neuroendocrine Cancer usually begins with surgery. Later, radiation therapy and chemotherapy are recommended as first-line treatments. Medication involving somatostatin analogues and targeted therapy are also recommended.
The pipeline of Neuroendocrine Cancer treatment market consists of a great variable of drugs. Angiogenesis inhibitors, Colony Stimulating Factor-1 Receptor (CSF-1R) inhibitors, Sphingosine 1-phosphate Receptor (S1PR) agonists, Programmed Cell Death Protein 1 (PD-1) antagonists, and some others are the most highlighted class of this indication. Ongoing research and current trials have the potential to change the market.
More than 30 key players, including pharma giants such as Boehringer Ingelheim, Jazz Pharmaceuticals, Merck, NexImmune, Roche and others are working to bring novel therapies that overcome the roadblocks of neuroendocrine cancer treatment pipeline.
Report Highlights
Global Insight Service’s, “Neuroendocrine Cancer – Drug Pipeline Landscape, 2023,” an overview of the Neuroendocrine Cancer pipeline drugs. This report covers detailed insights on Neuroendocrine Cancer drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to gain insights and thus help industry participants for decision making. Neuroendocrine Cancer pipeline report helps gaining insights on drugs which are under development stage of drug development process across globally. Global Insight Services aims to cover all the drug attributes, deals, regulatory milestones and all the upcoming milestones.
Recent Developments
In November 2022, Lantheus Holdings Inc entered into licensing agreement with POINT Biopharma, granting worldwide rights to develop PNT2003.
In October 2022, 23andMe Holding Co presented phase I trials on 23ME-00610 for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting to be held in Boston.
In October 2022, Phanes Therapeutics Inc received clearance from the US FDA to commence Phase I studies with PT217 which is developed for the treatment of small cell lung cancer and other neuroendocrine cancers.
In September 2022, RayzeBio Inc. announced significant progress in the clinical development of its lead candidate, RYZ101. The company is enrolling patients in the Phase Ib portion of the ACTION-1 Phase Ib/3 trial of RYZ101 (NCT05477576) in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
In February 2022, NexImmune Inc announced a collaboration with Rutgers, the State University of New Jersey to discover and develop novel therapies targeting immune checkpoint proteins for the treatment of Neuroendocrine Cancer and other cancers.
Key Products
Surufatinib is under development for the treatment of pancreatic (“pNETs”) and extra-pancreatic (non-pancreatic, “epNETs”) Neuroendocrine Cancer (“NETs”). Hutchmed Ltd received a complete response letter (CRL) from the US FDA in May 2022 regarding the New Drug Application (NDA) for surufatinib. In April 2020, the company received Fast Track Designations from the US FDA, and in November 2019, the company received an orphan drug designation from the US FDA.
ITM-11 is under development for the treatment of gastroenteropancreatic Neuroendocrine Cancer (GEP-NETs). In October 2022, ITM Solucin GmbH received Fast Track designation from the US FDA for ITM-11. In December 2021, ITM Isotope Technologies Munich SE and Grand Pharmaceutical Group Ltd have entered into an exclusive license agreement for GP to develop, manufacture and commercialize ITM-11 in the territory of mainland China, Hong Kong, Macau and Taiwan.
Tislelizumab is under development for the treatment of Neuroendocrine Cancer. In May 2020, Hutchinson China Meditech Ltd entered into clinical collaboration with BeiGene Ltd to evaluate the safety, tolerability and efficacy of surufatinib and fruquintinib with tislelizumab for the treatment of various solid tumor cancers, in the U.S., Europe, China and Australia.
Debio 4126 is under development for the treatment of Neuroendocrine Cancer. In January 2023, Debiopharm announced that it has dosed first patient with Debio 4126 for the treatment of acromegaly and 1 group with functioning GEP-NETs patients will receive 4 injections for a total treatment duration of 48 weeks.
| Drugs | Company | Phase | Molecule Type | MoA | RoA |
|---|---|---|---|---|---|
| Surufatinib | Hutchison Medipharma Ltd | Filing Rejected | Small Molecule | Angiogenesis Inhibitor, Colony Stimulating Factor-1 Receptor (CSF-1R) Inhibitor | Oral |
| ITM-11 | ITM Solucin GmbH | Phase III | Small Molecule | Sphingosine 1-phosphate Receptor (S1PR); Sphingosine 1-phosphate Receptor (S1PR) Agonist | Intravenous |
| Tislelizumab | BeiGene, Inc | Phase II | Monoclonal Antibody | Fc-Gamma Receptors (FcγR), Programmed Cell Death Protein 1 (PD-1); Fc-Gamma Receptors (FcγR) Antagonist; Programmed Cell Death Protein 1 (PD-1) Antagonist | Intravenous |
| Debio 4126 | Debiopharm | Phase I | Small Molecule | Adenylyl Cyclase (AC); Adenylyl Cyclase (AC) Inhibition | Intramuscular |
Figure: Number of Drugs for The Treatment of Neuroendocrine Cancer Under Each Stage of Development
Methodology
The research process includes extensive secondary research on public domain and other authentic sources carried out to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, clinical trials registries.
Scope
The pipeline landscape report consists of pipeline product based on several stages of development ranging from discovery to Pre-Registration. The report provides a review of pipeline therapeutics for Neuroendocrine Cancer by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of Neuroendocrine Cancer therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals and key upcoming milestones.
Reasons to Buy
Helps to find and recognize significant therapeutics under development for Neuroendocrine Cancer.
Thorough understanding of Neuroendocrine Cancer pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge on competitor information, analysis, and insights.
Plan of collaborations from various industry partners that have role in some or the other stage of drug development like contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Frequently Asked Questions
• What is Neuroendocrine Cancer?
• What are the Causes, Signs and Symptoms of Neuroendocrine Cancer?
• How is Neuroendocrine Cancer diagnosed?
• What are the most common treatments available for Neuroendocrine Cancer?
• How many/which companies are developing Neuroendocrine Cancer drugs?
• How many Neuroendocrine Cancer drugs are under development by each company and their stage of development?
• How many emerging drugs are in late-stage, mid-stage and early-stage of development for the Neuroendocrine Cancer treatment?
• What are the key collaborations, mergers and acquisitions, licensing activities related to the Neuroendocrine Cancer therapeutics?
• What are the molecule types, target, mechanism of action and route of administration of emerging drugs under development for the treatment of Neuroendocrine Cancer?
• What are the clinical studies available for Neuroendocrine Cancer and their status?
• What are the key regulatory designations that have been granted to the treatment emerging drugs?
• What are the key upcoming milestones for Neuroendocrine Cancer drugs?
• How many drugs are under Inactive or Discontinued for the treatment of Neuroendocrine Cancer?
Table of Contents
List of Table
List of Figures
1. Introduction
1.1 Neuroendocrine Cancer – Pipeline Drugs, 2023 – Coverage
2. Disease Overview – Neuroendocrine Cancer
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Neuroendocrine Cancer – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products Under Development by Companies, 2023
3.3 Products Under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.4 Assessment by Route of Administration
5. Drug Profiles
5.1 Late-Stage Drugs – Filing Rejected
5.1.1 Surufatinib
5.2 Clinical Stage Drugs – Phase III
5.2.1 CAM2029
5.2.2 ITM-11
5.2.3 PNT 2003
5.2.4 RYZ101
5.2.5 Toripalimab
5.3 Clinical Stage Drugs – Phase II
5.3.1 23ME-00610
5.3.2 AlphaMedix
5.3.3 Belzutifan
5.3.4 CVM-1118
5.3.5 Lurbinectedin
5.3.6 MRT-2359
5.3.7 Paltusotine
5.3.8 Pembrolizumab
5.3.9 Tislelizumab
5.3.10 Voyager-V1
5.4 Clinical Stage Drugs – Phase I
5.4.1 BI 764532
5.4.2 Debio 4126
5.4.3 Debio 4127
5.4.4 Ebtate
5.4.5 Mycapssa
5.4.6 Pelcitoclax
5.4.7 PV-10
5.4.8 RO7616789
5.4.9 SurVaxM
5.5 Early-Stage Drugs – IND/CTA Filed
5.5.1 PT217
5.6 Early-Stage Drugs – Preclinical
5.6.1 BG-P-TAT
5.6.2 CHM 2101
5.6.3 GP-2250
5.6.4 IDP 233
5.6.5 INV 200
5.6.6 ONCR 788
5.6.7 TE 8214
5.6.8 VMT-alpha-NET
5.7 Early-Stage Drugs – Discovery
5.7.1 Undisclosed
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 23andMe Inc
9.2 Amryt Pharma Group
9.3 Ascentage Pharma Group Inc.
9.4 BeiGene
9.5 Boehringer Ingelheim
9.6 Camurus AB
9.7 Chimeric Therapeutics
9.8 Crinetics Pharmaceuticals Inc.
9.9 Debiopharm International SA
9.10 Hoffmann-La Roche
9.11 Hutchison Medipharma Limited
9.12 IDP Pharma
9.13 Immunwork
9.14 INVENT Pharmaceuticals
9.15 ITM Solucin GmbH
9.16 Jazz Pharmaceuticals
9.17 Junshi Biosciences
9.18 Merck Sharp & Dohme LLC
9.19 MimiVax
9.20 Molecular Targeting Technologies, Inc
9.21 Monte Rosa Therapeutics, Inc
9.22 NanoPharmaceuticals
9.23 NexImmune, Inc.
9.24 Oncorus
9.25 Panavance Therapeutics
9.26 Phanes Therapeutics
9.27 POINT Biopharma Global Inc
9.28 Provectus Biopharmaceuticals, Inc
9.29 Radiomedix, Inc
9.30 RayzeBio, Inc.
9.31 TaiRx, Inc.
9.32 Viewpoint Molecular Targeting
9.33 Vyriad, Inc
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1.1 Number of Products Under Development by Neuroendocrine Cancer
Table 1.2 Number of Products Under Development by Companies
Table 1.3 Products Under Development by Companies
Table 1.4 Products by Targets
Table 1.5 Products by Mechanism of Action
Table 1.6 Products by Molecule Type
Table 1.7 Products by Route of Administration
Table 2.1 Clinical Trial Details – CAM2029/Camurus AB
Table 2.2 Clinical Trial Details – ITM-11/ITM Solucin GmbH
Table 2.3 Clinical Trial Details – PNT 2003/POINT Biopharma Global Inc
Table 2.4 Clinical Trial Details – RYZ101/RayzeBio, Inc.
Table 2.5 Clinical Trial Details – Toripalimab/Junshi Biosciences
Table 2.6 Clinical Trial Details – 23ME-00610/23andMe, Inc.
Table 2.7 Clinical Trial Details – AlphaMedix/Radiomedix, Inc
Table 2.8 Clinical Trial Details – Belzutifan/Merck Sharp & Dohme LLC
Table 2.9 Clinical Trial Details – CVM-1118/TaiRx, Inc.
Table 2.10 Clinical Trial Details – Lurbinectedin/Jazz Pharmaceuticals
Table 2.11 Clinical Trial Details – MRT-2359/Monte Rosa Therapeutics, Inc
Table 2.12 Clinical Trial Details – Paltusotine/Crinetics Pharmaceuticals Inc.
Table 2.13 Clinical Trial Details – Pembrolizumab/Merck Sharp & Dohme LLC
Table 2.14 Clinical Trial Details – Tislelizumab/BeiGene
Table 2.15 Clinical Trial Details – Voyager-V1/Vyriad, Inc
Table 2.16 Clinical Trial Details – BI 764532/Boehringer Ingelheim
Table 2.17 Clinical Trial Details – Debio 4126/Debiopharm International SA
Table 2.18 Clinical Trial Details – Debio 4127/Debiopharm International SA
Table 2.19 Clinical Trial Details – Ebtate/Molecular Targeting Technologies, Inc
Table 2.20 Clinical Trial Details – Mycapssa/Amryt Pharma Group
Table 2.21 Clinical Trial Details – Pelcitoclax/Ascentage Pharma Group Inc.
Table 2.22 Clinical Trial Details – PV-10/Provectus Biopharmaceuticals, Inc
Table 2.23 Clinical Trial Details – RO7616789/Hoffmann-La Roche
Table 2.24 Clinical Trial Details – SurVaxM/MimiVax
Table 3.1 Regulatory Designations
Table 4.1 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1.1 Number of Products Under Development for Neuroendocrine Cancer, 2023
Figure 1.2 Products by Top 5 Targets and Stage of Development for Neuroendocrine Cancer, 2023
Figure 1.3 Products by Top 5 Mechanism of Action for Neuroendocrine Cancer, 2023
Figure 1.4 Products by Top 5 Molecule Type for Neuroendocrine Cancer, 2023
Figure 1.5 Products by Top 5 Route of Administration for Neuroendocrine Cancer, 2023
Key Players
- 23andMe, Inc.
- Amryt Pharma Group
- Ascentage Pharma Group Inc.
- BeiGene
- Boehringer Ingelheim
- Camurus AB
- Chimeric Therapeutics
- Crinetics Pharmaceuticals Inc.
- Debiopharm International SA
- Hoffmann-La Roche
- Hutchison Medipharma Limited
- IDP Pharma
- Immunwork
- INVENT Pharmaceuticals
- ITM Solucin GmbH
- Jazz Pharmaceuticals
- Junshi Biosciences
- Merck Sharp & Dohme LLC
- MimiVax
- Molecular Targeting Technologies, Inc
- Monte Rosa Therapeutics, Inc
- NanoPharmaceuticals
- NexImmune, Inc.
- Oncorus
- Panavance Therapeutics
- Phanes Therapeutics
- POINT Biopharma Global Inc
- Provectus Biopharmaceuticals, Inc
- Radiomedix, Inc
- RayzeBio, Inc.
- TaiRx, Inc.
- Viewpoint Molecular Targeting
- Vyriad, Inc
Report Segmentation
- Assessment by Stage of Development
- Assessment by Companies
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Molecule Type
- Assessment by Route of Administration